Therefore, we next tested the effect of an anti-PD-L1 antibody (αPD-L1), atezolizumab, on KCa3.1 and Kv1.3 channels in activated CD8+ PBTs of HNSCC patients reasoning that if the effect of pembrolizumab is due to the disruption of PD-L1/PD-1 binding, a similar effect should be produced by αPD-L1. This evidence concerns the gene KCNA3 and head and neck squamous cell carcinoma.